For patients with significant asthma, the use of budesonide/eformoterol as both maintenance and reliever treatment is similarly effective to other management strategies in the achievement of good asthma control, while also reducing episodes of poor control and lessening overall treatment burden. The evidence suggests that the management of asthma should change unless there is an identifiable contraindication. Education, emphasising the sunplicity of this change in treatment, is critical to delivering the benefits. An opportunity is presented to widen the use of written asthma action plans.
|Number of pages||4|
|Publication status||Published - Apr 2008|